Board of Directors

Print page     Email page

show all hide all

Gerald P. Belle

Chairman

Gerald P. Belle was appointed Chairman of the Myrexis Board of Directors on February 19, 2009. Mr. Belle served as a director of Myriad Genetics from November 2007 until November 2009. He was previously President and Chief Executive Officer, North American Pharmaceuticals, Aventis, Inc. from 2000 to 2004. Over his 35-year career with Aventis and its predecessor companies, Mr. Belle's responsibilities included executive commercial and general management positions in the U.S., Asia, Europe/Middle East/Africa and Canada. Following his retirement from Aventis in November 2004, he was appointed Executive Chairman of Merial, Ltd., a global leader in animal health and a joint venture between Merck and sanofi-aventis. He retired from Merial, Ltd. in November 2007. Mr. Belle currently serves as the Chairman of the Board of Directors of PDI, Inc. Mr. Belle received his B.S. in Business from Xavier University, and his M.B.A. from Northwestern University.

Member of the Compensation Committee

Robert Forrester LL.B.

Robert Forrester, LL.B., joined the Myrexis Board of Directors on June 1, 2009. Mr Forrester is Chief Operating Officer of Forma Therapeutics, Inc. From February 2004 to January 2010, Mr. Forrester served as Interim President and Chief Executive Officer, and Executive Vice President and Chief Financial Officer of CombinatoRx, Incorporated. Prior to joining CombinatoRx, Mr. Forrester served as Senior Vice President, Finance and Corporate Development at Coley Pharmaceutical Group from 2000 to September 2003. Mr. Forrester was a Managing Director of the proprietary investment group at MeesPierson, part of the Fortis Group, from 1994 to 2000. Prior to MeesPierson, Mr. Forrester worked for BZW, UBS and Clifford Chance LLP. Mr. Forrester holds a LL.B. from Bristol University.

Chair of the Audit Committee
Member of the Compensation Committee

Timothy R. Franson M.D.

Timothy R. Franson, M.D. joined the Myrexis Board of Directors on September 10, 2009. Dr. Franson is Senior Vice President with B&D Consulting (Indianapolis IN and Washington DC). He also serves as President of the United States Pharmacopeial Convention (2010-2015) and as a Director for Quadraspec, Inc., a small technology firm in West Lafayette IN. Until his retirement in June 2008, Dr. Franson was with Eli Lilly and Company for over 20 years, most recently as Vice President of Global Regulatory Affairs and Drug Safety. Previous positions held at Lilly included Group Medical Director for Europe, Executive Director for North American Regulatory, Chemistry Manufacturing Control, Planning & Global Operations and Vice President of Clinical Research and Regulatory Affairs-US. Dr. Franson has served as chair of the Clinical Steering Committee and as a member of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers' Association (PhRMA) and until recently, chaired PhRMAs FDA Committee Staff Work Group (2000-2008). He was co-chair of the joint FDA-industry working group addressing clinical aspects of the FDA Modernization Act of 1997, including the Prescription Drug User Fee Act (PDUFA) renewal; and from 2000-2003 he co-chaired the overall industry-FDA committees for PDUFA-3 renewal. Dr. Franson received his undergraduate degree in Pharmacy at Drake University and his M.D. degree at the University of Illinois. He is Board Certified in Internal Medicine and Infectious Diseases and prior to joining Lilly was Assistant Professor of Medicine at the Medical College of Wisconsin where he was a member of the Governor's Task Force on AIDS. He was also an Assistant Professor of Medicine at Indiana University School of Medicine.

Member of the Nominating and Governance Committee

John T. Henderson M.D.

John T. Henderson, M.D., was appointed a member of the Myrexis Board of Directors on February 19, 2009. Since December 2000 Dr. Henderson has served as a consultant to the pharmaceutical industry as President of FuturePharm LLC. Until his retirement in December 2000, Dr. Henderson was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for the Europe, U.S. and International Pharmaceuticals groups at Pfizer. Dr. Henderson earned his bachelor's and medical degree from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.) and a Fellow of the Faculty of Phamaceutical Medicine. Dr. Henderson has served as a director of Myriad Genetics since May 2004 and Chairman of the Board of Directors since April 2005. He also serves on the Board of Directors of Cytokinetics, Inc.

Member of the Audit Committee
Chair of the Nominating and Governance Committee

Adrian N. Hobden Ph.D.

President, Chief Executive Officer and Director

Adrian N. Hobden, Ph.D., was appointed President, Chief Executive Officer and a Director of Myrexis, Inc. on February 19, 2009. Prior to this appointment, Dr. Hobden was President of Myriad Genetics' wholly-owned drug development subsidiary, Myriad Pharmaceuticals, and during his 10 years as President, he grew the organization to almost 200 people and put six compounds into clinical development. Dr. Hobden became the first employee of Myriad Pharmaceuticals in October 1998 after 17 years at Glaxo Wellcome, where he last held the position of Director of Global Biotechnology Ventures. Dr. Hobden's career at Glaxo included roles as head of Genetics, Molecular Science and Pharmacology Departments, Director of Biotechnology Ventures, head of drug discovery programs in HIV, anti-fungals and cardiovascular disorders and management of collaborations with several biotechnology companies. He received his Ph.D. in molecular biology from Leicester University and BA and MA degrees in biochemistry from Cambridge University.

Dennis H. Langer M.D., J.D.

Dennis H. Langer, M.D., J.D., was appointed a member of the Myrexis Board of Directors on February 19, 2009. From August 2005 to May 2010, Dr. Langer served as Managing Partner of Phoenix IP Ventures, LLC. From January 2004 to July 2005, Dr. Langer served as President, North America for Dr. Reddy's Laboratories, Inc. From September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline, and its predecessor, SmithKline Beecham, including most recently as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D. From 1991 to 1994, Dr. Langer was President and CEO of Neose Pharmaceuticals, Inc. From 1983 to 1991, Dr. Langer held positions in clinical research and marketing at Eli Lilly, Abbott and Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. Dr. Langer has served as a director of Myriad Genetics since May 2004.

Member of the Audit Committee
Member of the Nominating and Governance Committee
Chair of the Compensation Committee